Brief: Ultragenyx Announces The Publication Of A Successful 96-Week Randomized, Placebo-Controlled Trial With Crossover Treatment Of Genglycos™ (Also Known As Dtx401) Aav Gene Therapy In Gsdia In The Journal Of Inherited Metabolic Disease
01/09/2026 21:14
BRIEF-Ultragenyx Announces The Publication Of A Successful 96-Week Randomized, Placebo-Controlled Trial With Crossover Treatment Of Genglycos™ (Also Known As Dtx401) Aav Gene Therapy In Gsdia In The Journal Of Inherited Metabolic Disease Sept 1 (Reuters) - Ultragenyx Pharmaceutical Inc. RARE.O:
ULTRAGENYX ANNOUNCES THE PUBLICATION OF A SUCCESSFUL 96-WEEK RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH CROSSOVER TREATMENT OF GENGLYCOS™ (ALSO KNOWN AS DTX401) AAV GENE THERAPY IN GSDIA IN THE JOURNAL OF INHERITED METABOLIC DISEASE
Source text: ID:nGNX8dxKzN
Further company coverage: RARE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx